


THE LIVER GROUP
ANNUAL REPORT AND ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2009



THE LIVER GROUP

CONTENTS

Association Information	1
Report of the Trustees	2-4
Chairman's Report	5
Independent Auditor's Report	6-7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10-15

THE LIVER GROUP
ASSOCIATION INFORMATION
FOR THE YEAR ENDING 31 DECEMBER 2009

Patron: The RT Hon Lord Bingham of Cornhill
Senior Law Lord

Trustees: David Clifford
Jeff Faulkner – resigned 16 June 2009
Kay Glendinning MBE
Prof Humphrey Hodgson FRCP, F Med Sci
Prof David Kerr CBE
Prof Sir Roger Penrose OM FRS
Clare Selden PhD
Sarah Bates
Sue Eggleton – appointed 16 June 2009

Principal office: The Liver Group
Centre for Hepatology
Department of Medicine
Royal Free Campus
University College Medical School
Rowland Hill Street
Hampstead
London NW3 2PF

Charity registration number: 1024533

Bankers: HSBC
Oxford Circus Branch
London W1A 1EZ

CCLA Investment Management Ltd
80 Cheapside
London
EC2V 6DZ

Auditors: Andrew Wilson
Simpson Wreford & Co
Wellesley House
Duke of Wellington Avenue
Royal Arsenal
London SE18 6SS

THE LIVER GROUP**TRUSTEES' REPORT****FOR THE YEAR ENDING 31 DECEMBER 2009**

The Trustees submit their annual report and the audited financial statements for the year ended 31 December 2009. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" issued in 2005 in preparing the annual report and financial statements of the Charity which have been prepared under section 45 of the Charities Act 1993. The organisation is a Charity constituted under a Trust Deed dated 28 May 1993.

The administrative information set out on page 1 forms part of this report.

Objectives and activities

The objects of the charity are:

- i) The relief of patients suffering from disease of the liver and genetic defects affecting the liver
- ii) The promotion of research into the causes and treatment of diseases of the liver on terms that the results of such research are published.

The principal activity of the Charity currently is the project being conducted to develop an artificial liver. The artificial liver project is being carried out with the funds raised for the continuing "Liver for Life" Appeal.

The Board of Management comprises eight Trustees, seven elected, one co-opted. The members are able to draw on relevant board experience in board deliberations. The Board is collectively responsible for the competent management of the organisation in accordance with its objectives which are set out in the Trust Deed. The Board meets twice a year to monitor the organisation's strategy and activities.

The Charity does not have any employees and its day to day activities are carried out by University College London under the supervision of two Trustees. If the need arose to appoint a new trustee the remaining trustees would identify and appoint an appropriate person. The current Trustees are responsible for the induction of any new trustee which involves making them aware of the Trustees' responsibilities, the governing documents, administrative procedures and the history and philosophical approach of the charity. The Trustees have agreed a position that should any profits arise from the intellectual property in the research being carried out by the team, and in conjunction with the various other parties involved in that work, the Charity may/would be entitled to up to 50% of such amounts.

Achievements and performance

- Research output, intellectual property gained and achievement of milestones towards moving the Bioartificial Liver project from the bench to the bedside.
- Administrative charitable activities are limited to fundraising for the research endeavour. This is achieved by written applications to known grant giving organisations, small and large companies via the CEOs or other appropriate individual or wealthy individual donors. The Charity also has a web-page with an opportunity to donate via CAF. £157,016 (2008 £130,500) was raised in this financial year from donations; other income was generated from interest earned on cash deposits.
- Indicators of achievements are success in the research aims and, in addition, the total funds raised in a particular year. These rarely exceed our expenditure for the year.

THE LIVER GROUP**TRUSTEES' REPORT****FOR THE YEAR ENDING 31 DECEMBER 2009****(Continued)**

- The Charity is one of many sourcing the same research funding; given the difficult position most UK universities find themselves in, there is increasing competition for funds. Until government resources fill the gap between the costs and current funding of medical research the Charity's efforts will become more difficult each year. Notwithstanding this difficult climate, the Charity continues to explore every avenue to increase funding from grants and donations.

Financial review

The organisation is funded mainly by donations. They are a mixture of individual, corporate and charitable trust donations.

The majority of funds are spent on paying the salaries of researchers, as well as the required consumables and equipment for the research to continue. As evidenced by the publications, the Charity's current aim to develop a bioartificial liver machine (BAL) has moved forward from the very small scale to medium scale. The following period will see a scale up to human scale for this machine. Each of these steps is associated with a considerable increase in research personnel, consumable and equipment expenditure.

Except for such funds as the Trustees consider prudent to maintain for the purpose of management and administration of the Charity for the foreseeable future, all unrestricted funds are applied for the purposes of the "Liver for Life" project and the general charitable objects of the Charity.

As at 31 December 2009 the unrestricted fund had a surplus of £563,332 (2008 – £512,383), and the restricted fund has a surplus of £58,231 (2008 - £137,856). The Charity's unrestricted fund is already committed to existing research and PhD students and their necessary consumables.

Risk management

The Trustees confirm that there are ongoing processes for identifying, evaluating and managing significant risks faced by the organisation.

Public benefit

All the donations made by the Charity were in furtherance of the Charity's long term objective of providing the relief of patients suffering from diseases of the liver and genetic defects affecting the liver, and promoting research into the causes and treatment of liver disease. The Charity has complied with section 4 of the Charities Act 2006 having due regard of the public benefit guidance published by the Commission.

Plans for future periods

The Charity aims to continue its medical research goals, at a pace commensurate with funding opportunities. With appropriate funding it sees the bioartificial liver machine project reach the clinical trial assessment within five years.

THE LIVER GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDING 31 DECEMBER 2009

(Continued)

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' Report and the financial statement in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales required the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources of the charity for that period. In preparing these financial statements, the trustees are required to:


- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 1993, the Charity (Accounts and Reports) Regulation 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditors

A resolution to re-appoint Simpson Wreford & Co as auditors will be proposed at the next AGM.

The report was approved by the Trustees on 13.10.2010

and signed on their behalf by.....

Humphrey Hodgson
Trustee

THE LIVER GROUP
CHAIRMAN'S REPORT
FOR THE YEAR ENDING 31 DECEMBER 2009

This year has been a good year on the path to our goal, the creation of a bioartificial liver, using our innovative technique in which cultured liver cells are suspended within beads of the hydrogel alginate. And this work has become more timely, with the increasing recognition that liver disease is now a major health problem in the UK – in fact now amongst the 5 leading causes of death in adults, and the only one of those ‘top 5’ which is increasing in incidence.

I reported last year on the Grant we secured from the ‘New and Emerging Technologies’ programme of the NIHR, the National Institute for Health Services Research – the Research and Development arm of the National Health Service in England. That grant was to perform a ‘proof of principle’ study in a large animal (porcine) model, using our bio-artificial liver, at a scale only slightly smaller than that which will be required for use in man, and by careful observation demonstrate that the manifestations of liver failure can be reversed.

We started those studies in March 2009 - in collaboration with the University of Cape Town, using the laboratories built in recognition of Christian Barnard as he developed the techniques for the world’s first heart transplant. It has taken a major logistic effort to accumulate the equipment there – and each experiment will need the cells for the bio-reactor to be shipped from London. But by the end of 2009 those experiments had begun, keeping up with the strict milestones required by the Department of Health. As scientists we are very loathe to make any firm claims before the proposed experimental protocols have been completed, but cautious optimism would be a fairly accurate assessment of our state of mind! Our research team in London has worked incredibly hard to scale the bio-reactor up further to ‘man-size’, and I know all the other trustees join with me in expressing our thanks to them for their work in London and to all the collaborators we have enlisted in Cape Town.

I mentioned our disappointment last year that the grant funding from the NIHR came from a cash-limited pool, so we have continued to work to raise funds from our supporters to support key work in the laboratory, and we are enormously grateful for the donations we have received.

Once again, I express my immense gratitude to our supporters, without whom this work would not be possible, and to my fellow trustees for their dedication and help.



Humphrey Hodgson
Chairman

INDEPENDENT AUDITOR'S REPORT
TO THE TRUSTEES OF THE LIVER GROUP
FOR THE YEAR ENDED 31 DECEMBER 2009

We have audited the financial statements of The Liver Group for the year ended 31 December 2009 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. The financial statements have been prepared under the accounting policies set out therein and the requirements of the Financial Reporting Standard for Smaller Entities (effective April 2008).

This report is made solely to the Trustees, as a body, in accordance with Section 43 of the Charities Act 1993 and the regulations made under section 44 of that Act. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our audit work, for this report or for the opinions we have formed.

Respective responsibilities of the Trustees and Auditors

The Trustees' responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the Statement of Trustees Responsibilities.

We have been appointed under section 43 of the Charities Act 1993 and report in accordance with regulations made under that act. Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK & Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are prepared in accordance with the Charities Act 1993. We also report to you if, in our opinion, the information given in the Trustees' Report is not consistent with those financial statements, the charity has not kept sufficient accounting records, if the charity's financial statements are not in agreement with the accounting records or if we have not received all the information and explanations we require for our audit.

We read other information contained in the Annual Report, and consider whether it is consistent with the audited financial statements. The other information comprises only the Trustees' Report and the Chairman's Report. We consider the implications for our report if we become aware of any apparent misstatements or material inconsistencies with the financial statements.

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (UK & Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgments made by the Trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to the charity's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatements, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

INDEPENDENT AUDITORS' REPORT
TO THE TRUSTEES OF THE LIVER GROUP
FOR THE YEAR ENDED 31 DECEMBER 2009
(Continued)

Opinion

In our opinion the financial statements:

- give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice (applicable to Smaller Entities), of the state of the Charity's affairs as at 31 December 2009 and of its incoming resources and application of resources in the year then ended, and

- have been prepared in accordance with the Charities Act 1993.



SIMPSON WREFORD & CO
Statutory Auditors
Wellesley House
Duke of Wellington Avenue
Royal Arsenal
London SE18 6SS

Dated: 14 October 2010

THE LIVER GROUP

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2009

	Notes	Unrestricted Funds £	Restricted Funds £	Total 2009 £	Total 2008 £
Incoming resources	2				
<i>Incoming resources from generating funds</i>					
Voluntary income		107,016	50,000	157,016	130,500
Investment income		<u>5,757</u>	-	<u>5,757</u>	<u>38,714</u>
Incoming resources for the year		<u>112,773</u>	<u>50,000</u>	<u>162,773</u>	<u>169,214</u>
Resources expended	3				
Charitable activities		121,354	67,140	188,494	254,904
Governance costs		<u>2,955</u>	-	<u>2,955</u>	<u>2,300</u>
		<u>124,309</u>	<u>67,140</u>	<u>191,449</u>	<u>257,204</u>
Net outgoing resources for the year		(11,536)	(17,140)	(28,676)	(87,990)
Transfers	6	62,485	(62,485)	-	-
Fund balances at 1 January 2009		<u>512,383</u>	<u>137,856</u>	<u>650,239</u>	<u>738,229</u>
Fund balances at 31 December 2009		<u>563,332</u>	<u>58,231</u>	<u>621,563</u>	<u>650,239</u>

THE LIVER GROUP

BALANCE SHEET AT 31 DECEMBER 2009

	Notes	2009 £	2008 £
Current assets			
Cash at bank and in hand		<u>699,291</u>	<u>730,883</u>
Less: Creditors			
Amounts falling due within one year	4	<u>(77,728)</u>	<u>(80,644)</u>
Net assets		<u>621,563</u>	<u>650,239</u>
Financed by			
Unrestricted fund		563,332	512,383
Restricted funds	5	<u>58,231</u>	<u>137,856</u>
Total funds		<u>621,563</u>	<u>650,239</u>

These accounts were approved by the Trustees on 13.10.2010

Signed on their behalf by..... 

Clare Selden
Trustee

THE LIVER GROUP**NOTES TO THE FINANCIAL STATEMENTS****FOR THE YEAR TO 31 DECEMBER 2009****1. Accounting Policies****Basis of accounting**

The accounts have been prepared under the historical cost convention and in accordance with applicable Accounting Standards, the Charities Act 1993 and the Statement of Recommended Practice "Accounting for and reporting by Charities" (SORP 2005), and the Financial Reporting Standard for Smaller Entities (effective April 2008).

Voluntary income

Donations represent amounts received during the period and arise with the United Kingdom. Covenant and Gift-Aid income is included in gross attributable tax recoverable.

Investment income

Interest receivable is credited to income in the period in which it is earned and is included gross of attributable tax recoverable.

Charitable activities

Charitable activities are the research expenditure incurred on behalf of the Charity and recharged to The Liver Group by University College London (UCL). These are charged to the statement of financial activities (SOFA) on an accruals basis. This expenditure includes amounts paid for capital equipment and laboratory infrastructure which are regarded as expenditure in these accounts

Governance costs

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the costs related to the statutory audit.

Allocation of overhead and support costs

All overhead and support costs relate to governance costs and have been allocated as such (note 3).

Liabilities

Liabilities are recognised in the accounts where there is an obligation to transfer economic benefit.

Tangible fixed assets

Material items are capitalised where they are deemed to have a useful life of greater than a year.

Fund accounting

Total funds comprise the accumulated surplus or deficit on the statement of financial activities. Unrestricted funds are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity. Restricted funds are subject to specific restricted conditions imposed by donors. The purpose and use of these funds are set out in the notes to the accounts.

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2009

Taxation

The Charity is not liable to income tax on income derived from its charitable activities as it falls within the various exemptions available to registered charities.

The Charity is not registered for value added tax (VAT) and is therefore unable to reclaim the input tax it suffers on its purchases. Expenditure in the accounts is therefore shown inclusive of VAT where appropriate.

2. Incoming resources

	2009	2008
	£	£
Voluntary income		
The Steel Charitable Trust	-	10,000
The Coutts Charitable Trust	-	500
The Peter Stebbings Memorial Trust	50,000	50,000
The Eranda Foundation	-	50,000
Tom and Sheila Springer Charity	6,666	20,000
BS & IP Aynscombe	20	-
S & I Donald	250	-
Mr & Mrs Sutcliffe	30	-
Garfield Weston Foundation	100,000	-
CAF Bank	<u>50</u>	<u>-</u>
	<u>157,016</u>	<u>130,500</u>
Investment income		
Bank interest	<u>5,757</u>	<u>38,714</u>

3. Resources expended

	2009	2008
	£	£
Charitable activities		
Staff costs (employed on fixed term UCL contracts)	147,685	179,552
Research consumables and laboratory	<u>40,809</u>	<u>75,352</u>
	<u>188,494</u>	<u>254,904</u>
Governance costs		
Auditors' remuneration (including VAT)		
Accounting	962	805
Audit	<u>1,993</u>	<u>1,495</u>
	<u>2,955</u>	<u>2,300</u>

The average weekly number of employees of UCL working for The Liver Group during the year was 4 (2008: 5). At the year end there were 4 employees of UCL working on The Liver Group research. In addition there were 3 PhD students paid a stipend under a 3 year studentship scheme. There were no employees with remuneration above £60,000 for the year ended 31 December 2009

Trustees' expenses reimbursed during the year amounted to £Nil (2008: Nil).

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2009

4. Creditors

	2009	2008
	£	£
Accruals	2,656	2,300
Amounts due to UCL	<u>75,072</u>	<u>78,344</u>
	<u>77,728</u>	<u>80,644</u>

5. Restricted funds

	Balance at 1 Jan 2009 £	Income Resources £	Resources Expended £	Transfers £	Balance at 31 Dec 2009 £
Billingsgate Christian Mission Charitable Trust Studentship	1,500	-	-	-	1,500
Garfield Weston Foundation	53,866	-	(23,871)	(29,995)	-
Peter Stebbings Memorial Trust	50,000	50,000	(43,269)	-	56,731
Tom & Sheila Springer Charity	<u>32,490</u>	-	-	<u>(32,490)</u>	-
	<u>137,856</u>	<u>50,000</u>	<u>(67,140)</u>	<u>(62,485)</u>	<u>58,231</u>

All restricted funds have arisen from donations received by the Charity from the donors detailed above. The donation from Billingsgate Christian Mission Charitable Trust Studentship is for the use of a sandwich student. The donation from Garfield Weston Foundation is for the wages and consumables of a student, who was appointed on a 3 year contract which ended during the year. The donation from the Peter Stebbings Memorial Trust was for staff and consumables over a 3 year period. The donation from Tom & Sheila Springer Charity was for technical equipment which has now been acquired. Each fund is applied in accordance with the restrictions imposed.

6. Transfer

A transfer has been made between the restricted and unrestricted fund of £62,485. This represents the consumables expended since the grants were made which was in accordance with their restrictions. However the expenditure was recognised in the general fund in error in previous years and this transfer is a reallocation of these costs.

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2009

We are grateful to the following for donations to the “Liver for Life” Appeal:

Associated British Ports	Violet M Richards Charity
BAE Systems	Wilkinson Hardware Stores Ltd
Bank of England	Anonymous
Barclays Bank (Knightsbridge Limited)	Anonymous
Billingsgate Christian Mission Charitable Trust (The Fishmongers’ Company)	The Telegraph Plc
Boots Plc	The Bryan Guinness Charitable Trust
Bowring Plc	Pfizer Ltd
British Aerospace	Schroders Plc
BTR Plc	Brian Wright Esq
Charles Littlewood Charitable Trust	C E Heath Plc
Citybank	Morgan Crucible Company Plc
Clydesdale Bank/Yorkshire Bank	Honeywell Plc
Commercial Union	Thomson Corporation
Communis Plc	Life Technologies
Cookson Group Plc	Lloyds Bank Plc
Council of Forte Trust Fund	Price Waterhouse Plc
Courage Plc	IBJ
Coutts and Co	Seagrams Distillers Plc
D M Wilton	In Memoriam
Dako Limited	Jardine Insurance Services Ltd
Economist Plc	KPMG Pet Marwick
EJH Stephenson (Deceased) Charitable Trust	Laing, London
Friends Provident	Royal London Insurance Ltd
Glaxo Plc	Tomkins Plc
Guardian Royal Exchange Plc	Morgan Grenfell
HJ Heinz Co Ltd Charitable Trust	Robert Fleming Holdings Ltd
Hon C A Pearson’s Charity Trust	New Brunswick Plc
Mars UK Corporate Services Ltd	Sunlife Assurance Plc
Menzies Group	Smiths Industries
Rio Tinto Plc	Vauxhall Plc
Societe Generale United Kingdom Charitable Trust	Pharmaceutical Brand Consultancy Int
The Bergqvist Charitable Trust	The Really Useful Group Ltd
The Bowerman Memorial Trust	Richard Wilkinson Esq
The Clothworkers’ Foundation	Rudolf Wolff & Co Ltd
The Dunhill Medical Trust	Securicor Plc
The Fritton Trust	Special Trustees for Hammersmith & Acton Hospitals
The Garfield Weston Foundation	Racial Charitable Trust
The Haberdashers Company	TI Group
The Hamamelis Trust	Land Securities Plc
The Harnett Charitable Trust	Conoco Philips
The John Ellerman Foundation	Cooper Charitable Trust
The Mercers Company	The Mary Webb Trust
The Paul Balint Charitable Trust	The Oakdale Trust
The Sobell Foundation	Thriplow Charitable Trust
The Stella Symons Charitable Trust	The Penny in the Pound Fund Charitable Trust
The Thomas Sivewright Catto Charitable Settlement	N Smith Charitable Settlement
The Wolfson Foundation	The Gerald Palmer Trust
William & Mabel Morris Charitable Trust	Saddlers’ Company
The Childwick Trust	M E Rickman Trust
Tom & Sheila Springer Charity	Coutts Charitable Trust
	Steel Charitable Trust

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2009

We are grateful to the following for donations to the "Liver for Life" Appeal:

BS & IP

Aynscombe

S&I Donald

Mr & Mrs Sutcliffe

CAF Bank

The Eranda

Foundation

Peter Stebbings

Memorial Trust

THE LIVER GROUP**NOTES TO THE FINANCIAL STATEMENTS****FOR THE YEAR TO 31 DECEMBER 2009****Publications arising from the work of The Liver Group Charity in 2009**

Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma.

Coward SM, Legallais C, David B, Thomas M, Foo Y, Mavri-Damelin D, Hodgson HJ, Selden C.

Artif Organs. 2009 Dec;33(12):1117-26.PMID: 20078562

The role of the Bcl-3 proto-oncogene in thyroid hormone-induced liver cell proliferation.

Malik R, Bungay A, Sadiq A, Brown D, Riemann M, Choudhury S, Schmid R, Selden C, Hodgson H.

Artif Organs. 2009 Jun;33(6):425-30.PMID: 19473137

The use of 3-aminophthalimide as a pro-chemiluminescent label in chemiluminescence and fluorescence-based cellular assays.

Mavri-Damelin D, Wilden J, Mani AR, Selden C, Hodgson HJ, Damelin LH.

Bioconjug Chem. 2009 Feb;20(2):266-73.PMID: 19140729

A novel engineered form of hepatocyte growth factor, 1K1 protects human hepatocytes from apoptosis and promotes proliferation, and reverses fibrosis in vivo in mice - a prelude to a phase 1 clinical study.

Ross J, Gherardi E, Mallorqui N, Rees Myrddin, Hodgson HJF, Selden C.

Hepatology 2009 50: (4 suppl.) 227a

Engineered forms of hepatocyte growth factor protect human hepatocytes from apoptosis induced by Fas Ligand.

Ross J, Gherardi E, Rees Myrddin, Hodgson HJF, Selden C.

Presented at British Association for Study of Liver, 2009

Increased nuclear receptor expression improves inducible cytochrome P450 function in HepG2 cells to provide detoxificatory function relevant to clinical use.

Thomas, A, Ross J, Hodgson H, Selden C.

Presented at British Association for Study of Liver, 2009

A clinical scale Bioreactor for extracorporeal bioartificial liver support using liver derived human cell lines.

Erro E, Hodgson H, Molls R, Lubowiecki, Selden C.

Presented at British Association for Study of Liver, 2009